No ERISA pre-emption for inadequate care

FDA approves several drugs to treat rare conditions in both cancer and metabolic diseases.

Actions from FDA this week include approval of a second targted treatment for a Duchenne muscular dystrophy mutation, and filings in COVID-19 and blood disorders.

Adaptive Biotechnologies’ clonoSEQ gets third approval; FDA also acts on first at-home treatment for spinal muscular atrophy.

This month’s featured exec is Deborah Feldman, president and CEO of Dayton Children’s Hospital. Here, she sheds light on how the future of healthcare is shaping up, and how value-based care, the ACA, and pediatric pain management fit in.

Would you pay $19,900 to add another year to your life? If only it were that simple. The New England Journal of Medicine (NEJM) recently published a study that concluded between 1960 and 2000, we paid an average of $19,900 in medical costs per year of life gained during that time. In 1960, a newborn's life expectancy was 69.9 years, and in 2000, it was 76.87 years, according to the study.

Telemedicine programs decrease time-to-diagnosis, save financial resources and reduce hospital stays.